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Split hand–split foot malformation (SHFM) is characterized by hypoplasia/aplasia of the central digits with
fusion of the remaining digits. SHFM is usually an autosomal dominant condition and at least ﬁve loci have
been identiﬁed in humans. Mutation analysis of the DACTYLIN gene, suspected to be responsible for SHFM3
in chromosome 10q24, was conducted in seven SHFM patients. We screened the coding region of DACTYLIN
by single-strand conformation polymorphism and sequencing, and found no point mutations. However,
Southern, pulsed ﬁeld gel electrophoresis and dosage analyses demonstrated a complex rearrangement
associated with a 0.5Mb tandem duplication in all the patients. The distal and proximal breakpoints were
within an 80 and 130 kb region, respectively. This duplicated region contained a disrupted extra copy of
the DACTYLIN gene and the entire LBX1 and b-TRCP genes, known to be involved in limb development. The
possible role of these genes in the SHFM3 phenotype is discussed.
INTRODUCTION
Ectrodactyly or split hand–split foot malformation (SHFM) is a
human limb malformation characterized by hypoplasia/aplasia
of the central digital rays and variable fusion of the remaining
digits (MIM 183600). The condition occurs in 1 in 8500–
25 000 newborns and accounts for 8–17% of all limb reduction
defects (1–5). SHFM is clinically heterogeneous, presenting in
both non-syndromic and syndromic forms. The non-syndromic
form can be isolated (type I) or associated with long bone
deficiency (type II—also called SHFLD; MIM 119100) (6).
Among the several syndromes in which SHFM occurs, the
most common is the EEC (ectrodactyly, ectodermal dysplasia,
cleft lip/palate) syndrome (MIM 129900) (7).
When familial, SHFM is usually inherited in an autosomal
dominant manner with incomplete penetrance, variable expres-
sivity and segregation distortion with excessive transmission
from affected males to sons (6,8–10). An X-linked form has
been reported in a single family, and autosomal recessive
inheritance has also been described (11–14). To date, five loci
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for non-syndromic and syndromic SHFM have been identified
based upon linkage mapping and/or cytogenetic abnormalities:
SHFM1 on chromosome 7q21.3–q22.1 (15,16), SHFM2 on
Xq26 (11,13), SHFM3 on 10q24 (17,18), SHFM4 on 3q27
(19) and SHFM5 on 2q31 (20,21). P63, the gene responsible
for SHFM4 on 3q27, is the only gene thus far identified in
human SHFM (19,22). Interestingly, P63 mutations and
abnormalities at the SHFM1 locus cause both syndromic and
non-syndromic SHFM (22,23). In contrast, only non-syndromic
SHFM has been mapped to the SHFM3 locus (17,18,24).
Studies of the naturally occurring Dactylaplasia (Dac)
mouse, which has an SHFM-like phenotype, have been critical
to investigation of the SHFM3 locus. The mouse phenotype
bears striking similarity to typical human SHFM, with absence
of central digits, underdevelopment or absence of metacarpal/
metatarsal bones and syndactyly (25). The Dac phenotype is
inherited as an autosomal semidominant trait, with the more
severe phenotype (e.g. monodactyly) occurring in homozy-
gotes (26,27). The Dac locus was mapped to chromosome 19 in
a region syntenic to chromosome 10q24 in human (26).
Therefore, the Dac mouse is considered to be the mouse model
for SHFM3 in humans.
The Dac phenotype results from two different alleles, Dac1J
and Dac2J (27). Both alleles arise from a disruption of the
dactylin gene, which is a novel member of the F-box WD-40
protein family. F-box WD-40 proteins recruit specific target
protein(s) through their WD-40 protein-protein binding
domains for ubiquitin mediated degradation. The dactylin
protein appears to function in maintaining the apical ectoder-
mal ridge (AER) of the developing limb bud (27–29).
In humans, DACTYLIN has been mapped to the SHFM3
critical region (30) and is 87% identical to mouse dactylin at
the nucleotide level. DACTYLIN is considered to be the best
candidate gene for SHFM3 (27,30,31). To date, however,
mutations in DACTYLIN have not been reported in sporadic
cases of SHFM or familial cases mapping to the SHFM3 locus.
In this study, single-strand conformation polymorphism
(SSCP) and sequencing analysis of the entire DACTYLIN
coding region and flanking intronic sequences failed to detect
mutations in affected individuals from six families linked to the
SHFM3 locus. However, Southern analysis, pulsed field gel
electrophoresis (PFGE) analysis and dosage analysis demon-
strated complex rearrangements associated with large duplica-
tions of 10q24 in all six families and in an additional SHFM
family in whom linkage analysis was not possible. These
rearrangements create an extra copy of a portion of DACTYLIN,
an extra copy of the complete b-TRCP, POLL and LBX1 genes,
and an extra copy of a sequence located 400–550 kb
centromeric to DACTYLIN and constitute the first evidence of
genomic abnormalities within the SHFM3 critical region.
RESULTS
DACTYLIN analysis by SSCP and sequencing
No mutations were detected by either SSCP or sequencing in an
affected individual from each of the six SHFM3-linked
families. In patient LS, a g1134 G!A (p378T!T) change
was identified in DACTYLIN exon 9. However, this neutral
alteration was also found in a control individual.
Southern analysis
Southern analysis, using a variety of cDNA, exon-specific and
intron-specific DACTYLIN probes, (Fig. 1A) was performed on
an affected member of each linked family to screen for
alterations or rearrangements that would have been missed by
the SSCP and sequencing approaches. Altered bands were
identified in three patients (DF, TU and LS; Fig. 1B).
In patient DF, the cDNA probe containing DACTYLIN exons
1–4 detected an altered band with eight different restriction
enzymes (EcoRI, PstI, BamHI, BglI, BglII, HindIII, XbaI and
BclI). Using different probes containing exon 4 on an EcoRI
filter, an extra 9 kb band was present in DF (Fig. 1B) and all
affected members of the family, but was absent in the
unaffected members and in 46 control individuals (Fig. 1C
and data not shown). The EcoRI restriction map of the
DACTYLIN gene identified a 6.4 kb fragment containing exons
2, 3 and 4 (Fig. 1A). This fragment alone was detected with a
probe containing DACTYLIN exon 2, while the additional 9 kb
band was detected with probes containing either exon 3 or
exon 4 (Fig. 1A and B). Together, these results suggested
that affected members of this family had a 10q24 genomic
alteration in the 2.6 kb region between DACTYLIN exons 2 and 3
(Fig. 1A).
In patient TU, the DACTYLIN intron 5 probe detected an
altered band with two different enzymes (EcoRI and PstI). On a
PstI filter, this probe identified an extra 4.2 kb band (Fig. 1B)
that segregated with the SHFM phenotype (data not shown).
The PstI restriction map of DACTYLIN identified a 5.4 kb
fragment containing exon 5 and the region corresponding to the
intron 5 probe (Fig. 1A). Only the normal band was detected
with an exon 5 probe, thus localizing a genomic alteration in
this family to the 2 kb region between the exon 5 and intron 5
probes (Fig. 1A).
In patient LS, the probe containing DACTYLIN exon 1
detected an altered band with three different enzymes (HpaI,
EcoRI and BclI). On an HpaI filter, this probe identifed an extra
10 kb band (Fig. 1B) that was not detected in 46 control
individuals (data not shown). The HpaI restriction map of
DACTYLIN identified a 14.9 kb fragment containing exon 1
(Fig. 1A). A probe located 10 kb upstream of exon 1, between
the 50 HpaI site and exon 1, did not hybridize to the 10 kb band,
thus localizing a genomic alteration to the 11 kb region
between the DAC 50 probe and exon 1 (Fig. 1A).
Southern analysis of patients DH, VB and AC did not reveal
any altered bands using cDNA probes containing exons 1–4 or
exons 4–8 on EcoRI, BamHI, XbaI, HindIII, NcoI and NdeI
filters.
Subgenomic library construction and characterization
of a shifted band in patient DF
A subgenomic library for patient DF was constructed by cloning
EcoRI genomic fragments, ranging from 8 to 10 kb, into a
lambda vector in order to further characterize the 9 kb EcoRI
fragment. Screening of this library with the DACTYLIN exon 4
probe identified a clone containing a 9.2 kb insert. Sequencing
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of this clone revealed an extra 5.2 kb sequence adjacent to 4 kb
of DACTYLIN sequence which contained exons 3 and 4, intron 3
and adjacent portions of introns 2 and 4 (Fig. 2A). The
breakpoint in DACTYLIN was located at position 871 125 bp on
contig NT_033229, 1620 bp 50 of exon 3 (Fig. 2B). To confirm
the rearrangement, PCR primers were designed in the new
sequence and DACTYLIN intron 2 (Fig. 2A) and successfully
amplified the expected 5.4 kb product in patient DF but not in a
control individual (Fig. 2C). As additional confirmation, a probe
to the extra 5.2 kb sequence (Cent1) hybridized to the 9 kb band
previously detected with the DAC exon 4 probe in patient DF
(Fig. 2D). Together, these data demonstrated the presence of an
extra sequence disrupting the DACTYLIN gene between exons
2 and 3.
A BLASTN analysis (www.ncbi.nlm.nih.gov/blast) of this
extra 5.2 kb sequence identified the BAC clone RP11-31L23
Figure 1. Southern analysis of SHFM patients DF, TU and LS. (A) Restriction map of the DACTYLIN gene (only the relevant enzyme sites are represented).
E¼EcoRI, P¼PstI and H¼HpaI. Scoring for presence (þ) or absence () of the altered band using cDNA, exon-specific, and intron-specific DACTYLIN probes
on an EcoRI filter localized the breakpoint (BP) region for each patient. (B) Southern hybridization of patients DF, TU and LS with probes DAC cDNA exon 4,
DAC int 5 and DAC cDNA exons 1–4 respectively. The presence of an extra band in all three patients is indicated by the arrow. For patient DF, both the extra and
control bands are present in the mouse–human monochromosomal hybrid cell line containing the affected chromosome (chromosome 10B), while only the normal
band is present in the cell line containing the unaffected chromosome (chromosome 10A). The 10.2 kb band comes from mouse DNA. (C) Pedigree of DF’s family
and Southern hybridization with DAC exons 2–4 probe of an EcoRI filter. The 9 kb band is present only in the affected members of the family, which confirms
segregation of the rearrangement within the family: solid symbols, affected individual; open symbols, normal.
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(GenBank no. AL357395), which is part of contig NT_033229
that also contains DACTYLIN. This extra sequence is 570 kb
centromeric to DACTYLIN, and the centromeric breakpoint in
patient DF was located at position 300 773 bp on contig
NT_033229 (Figs. 2B and 3A) in what we now refer to as the
centromeric region.
PFGE analysis
The rearrangements detected in patients DF, TU and LS were
further characterized by PFGE analysis. In addition, the other
SHFM patients were included in this analysis to complete the
mutational screening of DACTYLIN.
On a NruI filter, DACTYLIN cDNA probe DAC 4–8 (exons
4–8) detected extra fragments in patients DF, TU and LS, as
anticipated from the Southern analysis, as well as in patients
VB, DH and AC (Fig. 4A). For patient RH, a DACTYLIN exon
6 probe detected an extra fragment on an NruI filter which was
also present in his affected mother but absent in his unaffected
father (data not shown). The altered fragments present in all
seven SHFM patients were similar in size ranging from 550
to 610 kb (Fig. 4A) and none of these was detected in nine
control individuals. In patients DF and TU, probe Cent1,
located 550 kb centromeric to DACTYLIN, recognized the
altered band previously detected with probe DAC 4–8 (Fig. 4A).
In all seven SHFM patients, probe Cent2, located between
DACTYLIN and Cent1, hybridized to the extra fragments
previously detected with DACTYLIN probes (Fig. 4A and B).
Together these data suggested that the seven SHFM patients
have a similar rearrangement involving the DACTYLIN gene
and a sequence located 460 kb (Cent2)–570 kb (Cent1)
centromeric to this gene.
Multiple hybridizations with probes located throughout the
centromeric region and DACTYLIN were used to refine the
breakpoint regions in each patient. Scoring of the presence or
absence of the altered band narrowed the breakpoint locations
in the centromeric and the DACTYLIN regions. A polymorphic
band (c) of 550 kb was found in two controls and in patient
AC using DACTYLIN probes and probes located 50 of
DACTYLIN (Fig. 4A). In patient AC, the altered band could
be distinguished from this polymorphic band because of a
significant difference in size resulting in a doublet (c and d)
(Fig. 4A). However, in patients LS and VB the presence of this
polymorphic band interfered with the scoring for presence/
absence of the altered band derived from the rearrangement and
previously detected with the Cent2 probe.
Identification of the breakpoint junction in patient TU
Additional probing of an MluI filter identified the centromeric
breakpoint in patient TU within a 24 kb region between the
probe Cent13 (289 044–289 478 bp of contig NT_033229) and
Figure 2. Characterization of the 9 kb altered band detected on an EcoRI filter in patient DF. (A) Schematic of the insert of the clone containing the 9.2 kb altered
band (estimated to be 9 kb by Southern). An extra sequence of 5.2 kb, located 570 kb centromeric of the DACTYLIN gene, was adjacent to DACTYLIN intron 2.
(B) Sequence of the breakpoint junction with the base pair position of the parental strand on the NT_033229 contig sequence. Sequence in italics represents the
centromeric region located in database (AL357395). (C) PCR analysis using primer A (in the DACTYLIN gene) and B (in the centromeric sequence) from (A)
revealed a PCR product of 5.4 kb only in patient DF but not in a control individual. (D) Southern blot analysis of EcoRI digested DNA from a control and patient
DF using probe DAC exon 4 (left) or probe Cent1 located within the centromeric sequence (right). Both probes hybridize to the 9.2 kb band.
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the next MluI site at position 264 876 bp (data not shown).
Restriction map analysis of the 24 kb centromeric breakpoint
region revealed 2 EcoRI and 2 PstI sites that were in the middle
of the region. Southern analysis in patient TU demonstrated the
presence of an altered band on an EcoRI filter (2.5 kb) and a
PstI filter (4.2 kb) using the probe DAC int5 (Fig. 1B and data
not shown). These findings suggested that the centromeric
breakpoint is located in the vicinity of these EcoRI and PstI
sites. PCR analysis was then performed using a primer located
within the centromeric region containing the EcoRI and PstI
sites and another primer located in intron 5 of DACTYLIN. A
2.1 kb band was amplified only from patient TU genomic DNA
but not in DNA from two control individuals (data not shown).
The sequence of this 2.1 kb band identified the breakpoint
junction between DACTYLIN and the centromeric sequence
(data not shown). The DACTYLIN breakpoint was located at
position 863 909 bp of contig NT_033229, 2 kb downstream of
exon 5. The centromeric breakpoint was located at position 282
974 bp, 18 kb from the centromeric breakpoint in patient DF
(Fig. 3B).
Based upon PFGE results in the other five patients, the
DACTYLIN breakpoints are within a 78.7 kb region between
the probe DAC 50 (position 899 507–900 982 bp) and
DACTYLIN exon 6 (position 820 652–820 913 bp; Fig. 3B).
The centromeric breakpoints are within a 129.5 kb region
between probe Cent6 (position 412 476–413 463 bp) and
position 282 974 bp, the breakpoint identified in patient TU
(Fig. 3B).
Figure 3. Computer-based sequencing of the SHFM3 critical region and breakpoint locations. (A) From top to bottom: the position of the STS markers, the BAC
clones with their accession number assembled into the NT_033229 contig. Only the SHFM3 possible candidate genes are represented. PAX2, HUG1, HOX11,
b-TRCP and NFkB2 are in a centromeric to telomeric orientation. LBX1, DACTYLIN, FGF8, POLL and LDB1 are in telomeric to centromeric orientation.
(B) location of the common duplicated region with the breakpoint (BP) regions (shaded boxed). The fine mapping of the breakpoint location for each patient
is also represented (shaded arrows). Based upon the band sizes observed in the presence and absence of 5-azaC hypomethylating agent (data not shown), it
was evident that the MluI site located between DACTYLIN and b-TRCP and the 2 NruI sites 50 of DACTYLIN are methylated (asterisk).
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Southern analysis of human–mouse hybrid cell lines
Dosage analysis of an EcoRI filter revealed that the intensity of
the normal DACTYLIN band was two to three times greater
than the intensities of either altered band detected in DF and
TU (data not shown). This finding suggested that DACTYLIN
was present in more than two copies in patients DF and TU.
This possibility was further tested using hybrid cell lines
generated from these two patients. For patient DF, all four
hybrid cell lines carried only one chromosome 10: two carried
the chromosome 10 arbitrarily called ‘A’ and two carried the
chromosome 10 called ‘B’. Chromosome 10B was considered
the affected chromosome since it contained DNA marker
alleles segregating with the phenotype (data not shown).
Southern analysis was performed with EcoRI and BamHI using
genomic DNA from a control individual and patient DF and
DNA from two hybrids and a mouse fibroblast cell line (E2).
On the EcoRI filter, a DACTYLIN exon 4 probe detected the
extra 9 kb band and the normal 6.4 kb band in patient DF and
cell line DF-Chr10B1, while only the normal band was seen in
the control individual and cell line DF-Chr10A1 (Fig. 1B).
An extra 10.2 kb band was seen only in the hybrid cell lines and
in the mouse control because of cross hybridization with the
dactylin mouse gene (Fig. 1B). On the BamHI filter, the same
probe detected the extra 15 kb band and the normal 30 kb band
in patient DF and cell line DF-Chr10B1, while only the normal
band was seen in a control individual and cell line DF-Chr10A1
(data not shown). The presence of both the normal and altered
bands in DF-Chr10B1 corresponding to the affected chromo-
some 10 suggested that at least a portion of DACTYLIN is
duplicated on the affected chromosome in patient DF.
Interestingly, on both EcoRI and BamHI filters, the Cent1
probe detected 2 bands (the normal band and an extra band) in
patient DF and DF Chr10B1, while only the normal band was
detected in the control individual and DF-Chr10A1 (data not
shown). The presence of both bands in DF-Chr10B1 suggested
that the centromeric sequence is also duplicated on the affected
chromosome in patient DF.
For patient TU, similar hybrids were created and Southern
analysis was performed using DACTYLIN probes on PstI and
EcoRI filters. Both normal and shifted bands were detected in
the hybrids containing the affected chromosome, while only
the normal band was detected in the hybrids containing the
unaffected chromosome (data not shown). As in patient DF,
the results were consistent with the presence of a partial
DACTYLIN duplication on the affected chromosome.
Dosage analysis by slot-blot
Although the hybrid cell line studies demonstrated the presence
of an extra copy of a portion of DACTYLIN on the affected
chromosome of patients DF and TU, the exact DACTYLIN copy
number in these patients could not be determined by dosage
analysis of the Southern blots. Dosage analysis using a slot-blot
method (32–34) was undertaken to determine if a duplication
of DACTYLIN existed independent of the rearrangement or if
the extra copy of DACTYLIN resulted from the rearrangement.
Hybridization of a filter containing genomic DNA from DF
and two control individuals with DAC exon 4 probe revealed a
statistically significant increase of the slope in patient DF,
suggestive of an extra copy of the DACTYLIN exon 4 region
in this patient (Fig. 5B and data not shown). A 3:2 ratio was
observed between the slope observed in patient DF and in a
control individual. This indicated that three copies of this
portion of DACTYLIN are present in patient DF and two copies
are present in the control individual and a trisomy 21 control. A
DACTYLIN intron 2 probe, located on the other side of the
breakpoint, is not duplicated in patient DF since no significant
differences between the slopes were detected (Fig. 5C and data
not shown). Furthermore, probe Cent1 is also duplicated while
probe Cent12, localized on the other side of the centromeric
breakpoint, is not (Fig. 5D and E and data not shown). Further
Figure 4. PFGE analysis of samples from seven SHFM patients, digested with
NruI. (A) Analysis of 6 SHFM patients (DF, TU, LS, VB, DH and AC) with
probes DAC cDNA exons 4–8, Cent 1, Cent 2 and b-TRCP exon1 were used.
The presence of two bands (a and b) around 800 kb is due to the presence of a
methylated NruI site located 50 of the FGF8 gene. A polymorphic band (c) is
present in both control individual 2 and patient AC. Patient AC’s altered band
(d) is lower than the polymorphic band (c), resulting in the presence of a doub-
let (detected with DAC 4–8 and b-TRCP probes). For patients LS and VB, the
distinction between the altered band (detected with Cent 2 or b-TRCP probes)
and the polymorphic band could not be performed when using DACTYLIN spe-
cific probes. (B) Pedigree of RH’s family and PFGE hybridization with Cent2
of a NruI filter. The 600 kb band is only present in the affected mother and the
proband, which confirms segregation of the rearrangement within the family.
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hybridization with a b-TRCP cDNA probe, located between
DACTYLIN and Cent1, was performed and an increase of the
slope was observed in patient DF (data not shown). Together,
these data indicated that in patient DF the entire region between
the DACTYLIN and the centromeric breakpoints is duplicated
on the affected chromosome. This 570 kb duplicated region
contains a portion of the DACTYLIN gene (exon 3 to the 30-
UTR), the complete b-TRCP and POLL genes as well as LBX1,
HUG1 and HOX11 genes which are centromeric to DACTYLIN.
Slot blot analysis was then performed on the other six
patients. In patients TU, LS, AC, DH and RH the region located
between the DACTYLIN and centromeric breakpoints in each
patient was also found to be present in three copies (data not
shown). The dosage data were also used to narrow the
DACTYLIN breakpoint region in patient VB that could not be
determined by PFGE analysis.
DISCUSSION
A common genomic rearrangement was demonstrated to be
associated with the SHFM phenotype in seven patients by
using Southern, PFGE and dosage analyses as well as human–
mouse hybrid cell lines containing a single chromosome 10 for
two patients (DF and TU). The sequencing of the breakpoint
junction in the same two patients revealed an extra sequence
that is adjacent to DACTYLIN. This extra sequence is normally
located 570 kb centromeric to DACTYLIN. In the other five
SHFM patients, the juxtaposition of both centromeric and
DACTYLIN sequences was demonstrated by PFGE analysis.
Additionally, Southern analysis of the single chromosome 10
hybrid cell lines of patients DF and TU and slot blot analysis of
all seven patients demonstrated that the region located between
the centromeric and DACTYLIN breakpoints is duplicated on
one chromosome 10 in all the patients. Based on these findings,
a model of an unequal recombination between the centromeric
and DACTYLIN regions resulting in a tandem duplication is
proposed to explain the rearrangement seen in these patients
(Fig. 6). This model is consistent with the orientation of the
sequences at the breakpoint junction, the size of the bands
observed by PFGE and the duplication findings. The tandem
duplication is likely the disease causing event for several
reasons: (1) it segregates with the SHFM phenotype in the three
families tested (DF, TU and RH); (2) the rearrangements
detected in DF and LS were not detected in 46 control
individuals; (3) the duplication is located on the affected
chromosome, as demonstrated by the use of single chromo-
some 10 hybrid cell lines in patients DF and TU; and
(4) none of the rearrangements detected by PFGE analysis in
the seven SHFM patients was found in nine control individuals.
Patient DH has the smallest duplicated region (440 kb) which
defines the minimal duplicated region common to all patients.
This narrows the number of genes included in the duplicated
region to LBX1, b-TRCP, POLL and a portion of the
DACTYLIN gene (exon 9 to exon 6) involving a region of
0.5 Mb (Fig. 6).
Figure 5. Graphical analysis of the densitometric values of test probes (y axis) vs the reference probe D4S12. In (A), the test probe is APP, a chromosome 21
specific probe; DAC exon 4 in (B); DAC intron 2 in (C), Cent1 in (D) and Cent12 in (E). (Diamond) Control; (Triangle) trisomy 21 individual; (Square) patient
DF. In (A) the slope for the trisomy 21 patient is shifted, demonstrating duplication for the APP probe region in this patient. In (B) and (D) the slope for patient DF
is shifted for probes DAC exon 4 and Cent1, respectively, but not for probes DAC intron 2 and Cent 12 in (C) and (E), respectively. The latter two probes are located
on the other side of the DACTYLIN and centromeric breakpoints, respectively.
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Several other disorders have been reported to be associated
with a submicroscopic duplication, deletion or inversion
(35–37). These disorders are categorized as being genomic
disorders in contrast to classic mendelian diseases (35).
Regions of high similarity (>90% at the nucleotide level),
known as low-copy repeats (LCRs), flank the genomic regions
involved in the rearrangements (36,37). Indeed, misalignment
and reciprocal recombination of these LCRs give rise to
duplication, deletion or inversion of the regions flanked by
these repeats (36–38). LCRs vary in size from 1 to 400 kb and
can contain genes, pseudogenes, gene clusters or retroviral
sequences. The tandem duplication detected in the SHFM
patients suggests a similar mechanism for the rearrangements
created by unequal crossing over events between highly similar
regions of >1 kb and >90% identity. To look for LCRs in this
region of chromosome 10, the 1.2 Mb of genomic sequence
encompassing 300 kb on either side of both breakpoint
regions was analyzed using the DNA sequence comparisons
program Miropeats (39). However, no evidence for the
existence of such LCR sequences was identified, making it
unlikely that LCRs mediate the rearrangements detected in the
SHFM patients.
Several genomic rearrangements involving tandem duplica-
tions have been attributed to homologous recombination
between Alu elements (40–45). Alu elements are the most
abundant class of interspersed repeat sequences and represent
5–10% of the human genome. However, some regions that are
prone to chromosomal rearrangement, like the chromosome
22q11 region, have more than 20% Alu elements. Using
repeatmasker software (http://ftp.genome.washington.edu/
cgi-bin/RepeatMasker), the repeat content of 100 kb of genomic
sequence containing each breakpoint region was analyzed for
interspersed repeat elements, and a high density of Alu
elements (20%) was observed in both regions. This finding
suggests that the rearrangement detected in the SHFM patients
may be mediated by an unequal homologous recombination
between Alu elements located in the centromeric and
DACTYLIN regions. However, analysis of the sequence of the
breakpoint junction in patients DF and TU did not detect any
residual Alu elements common to both parental strands or
within 50 bp of the junctions. This would suggest instead a
non-homologous recombination that may still be mediated by
the repetitive elements. The mechanism of non-homologous
recombination is poorly understood. It is believed to be a two-
step process with chromatid cleavage in the first step and
rejoining in the second (46). This process would explain why
no recombination hot-spots (<2 kb) were found in the seven
SHFM patients in contrast with other disorders involving
homologous recombination (47,48). However, the breakpoints
were still relatively clustered within over a region of 100 kb.
It is likely that the high density of repetitive elements in the
region is responsible for bringing together the centromeric and
DACTYLIN regions that are >400 kb apart, consequently
favoring non-homologous recombination.
How the duplication leads to the SHFM phenotype is
unknown. DACTYLIN is the best candidate gene for SHFM3
because of its role in the Dactylaplasia mice phenotype (27),
which is presumed to be the animal model for SHFM3 (26).
The Dac phenotype results from one of two different alleles,
Dac1J and Dac2J and both heterozygous mice for Dac1J and
Dac2J have an identical phenotype (27). The evidence suggests
that the Dac2J allele causes the Dac phenotype by abolishing
the normal dactylin transcript and/or creating a novel transcript.
However, it is unclear if the Etn transposon insertion in the
Dac1J allele is the disease-causing mutation, since homozygote
Dac1J mice expressed normal levels of the dactylin transcript
Figure 6. Model of the tandem duplication detected in the seven SHFM patients created by an unequal recombination between sequences of the centromeric region
and sequences of the DACTYLIN gene region. (A) Misalignment of the DACTYLIN and the centromeric sequences. (B) Result of an unequal recombination between
the DACTYLIN and the centromeric sequences. The expected sizes of the NruI bands are indicated and the observed NruI band sizes are indicated in brackets.The
asterisks define the methylated sites. The double-dagger symbol defines the expected and observed extra NruI fragment that is detected only in the SHFM patients.
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and no aberrant transcript was detected (27). In conjunction
with this observation, our findings further question the role of
dactylin in the Dac phenotype and DACTYLIN in human
SHFM3, since they demonstrate partial DACTYLIN duplica-
tions in all patients tested. In five patients, extra DACTYLIN
material is disrupted between exons 2 and 6 and in two patients
the breakpoint is located no more than 8 kb upstream of the first
exon. If DACTYLIN itself causes SHFM, it is possible that the
rearrangements alter limb development by creating an aberrant
DACTYLIN transcript that acts through a dominant negative
mechanism. However, such a transcript has yet to be detected in
our patients (data not shown) or in Dac1J mice (27).
Alternatively, the presence of a tandem duplication in the
SHFM patients suggests that overexpression of another
candidate gene may be responsible for the SHFM3 phenotype
and possibly the Dac phenotype if dactylin itself is an innocent
bystander in the Dac2J mouse. LBX1 and b-TRCP are two
potential candidate genes located in the duplicated region.
LBX1 is a homeobox gene and plays an important function in
developmental processes (49). However, this gene is mainly
expressed in the central nervous system and its expression in
the limb bud is restricted to the early myogenic cells, likely
ruling out this gene as responsible for SHFM3 (49–51).
b-TRCP is an F-Box-WD40 protein, like DACTYLIN, that is
involved in the NFkB signaling transduction pathway. Several
reports demonstrated a direct role of the NFkB pathway in limb
development (52–56). Interestingly, three genes of the NFkB
pathway (IKKa, NFkB2 and b-TRCP) are within the critical
region of SHFM3 defined by linkage mapping studies. IKKa
knockout mice display severe limb and skin abnormalities. The
NFkB pathway affects limb development by stimulating the
expression of SHH and repressing the expression of BMP4 in
the underlying mesenchyme (52). Therefore, NFkB activity is
likely critical for the maintenance of the apical ectodermal
ridge (AER) by controlling the expression of SHH and BMP4.
The Dactylaplasia mouse phenotype, and probably the SHFM3
phenotype in human, is caused by a defect in the maintenance
of the AER (29). Overexpression of b-TRCP may disrupt NFkB
activity giving rise to the SHFM3 phenotype. If this is the case,
patients with trisomy of the 10q24 region, containing the
b-TRCP gene should display an SHFM-like phenotype. One
patient with a de novo tandem duplication 10q24–q26 most
likely including the b-TRCP gene had mental retardation and
characteristic facial features of the duplication 10q syndrome
and minor malformation of the hands and feet (57). This patient
had proximally implanted thumbs and toes, camptodactyly, a
wide space between the first and second toes and syndactyly of
the second and third toes (57). However, characteristic features
of SHFM such as absence of the central digits and wide clefts
in the hands/feet were not reported. Therefore, this patient does
not seem to have a typical SHFM phenotype that would argue
for a causative role of a dosage effect of b-TRCP in the SHFM3
phenotype. However, the existence of a modifier locus for
SHFM3 (25) may complicate the phenotypical analysis of this
patient; indeed this patient may not display a SHFM phenotype
because of his genotype at the modifier locus.
A cis-acting positional effect may be another mechanism
that would cause the SHFM3 phenotype by disrupting the
expression of the genes flanking the breakpoints of the
duplication. Interestingly, the 400 kb proximal and distal
flanking regions harbor numerous candidate genes with known
or putative roles in limb development (Fig. 3A). FGF8 maps
to the critical region of SHFM3 as defined by linkage
mapping and its role in initiation, growth and patterning of
the limb is extensively documented (58–60). However, direct
sequencing and Southern analysis in SHFM3 patients did not
reveal any mutations, ruling out this gene as the major cause
of SHFM3 (61,62, Gurrieri and Schwartz, unpublished data).
Suppressor of Fused (SUFU) is also located within the critical
region and acts as negative regulator of the SHH pathway.
However, SUFU mutations were recently found in patients with
medulloblastoma (63) and no mutations were found among
SHFM3 patients (62,64). HOX11 is mainly expressed in T-cells
and disruption of this gene caused acute lymphoblastic
leukemia in a patient with a chromosomal translocation
t(10;14) (65). More importantly, the HOX11 murine homolog,
tlx1, is not expressed in the limb bud and tlx1 knockout mice
did not display any limb phenotype, arguing against a causative
role of HOX11 (particularly through a loss of function
mechanism) in SHFM3 (66).
Given the organization of the SHFM3 critical region, which
contains multiple genes involved in the NFkB pathway and
in limb development, it is conceivable that more than one gene
in the region may be involved in the same pathway leading to
SHFM. Hence, the Dac phenotype may be caused by two
different mechanisms. For example, the Dac2J allele may cause
limb malformation through loss of dactylin function and/or
production of an aberrant transcript, while the Dac1J allele may
cause increased dosage of a neighboring gene that normally
downregulates dactylin or is downregulated by dactylin. In the
families that we have studied, SHFM3 could result from either
mechanism.
An important consequence of this study is the possible use of
PFGE analysis with either DACTYLIN or centromeric probes
for SHFM3 diagnosis. The novel NruI fragment observed by
PFGE analysis with the probe Cent2 may be the best approach
for SHFM3 diagnosis. Indeed, probe Cent2 detected an altered
fragment in all the SHFM patients and the distinction between
the normal and altered bands was fairly easy to ascertain.
However, PFGE analysis requires the use of lymphoblastoid
cell lines and these are not always available. An alternative
approach would be to perform dosage analysis of the region
using slot blot analysis or real time quantitative PCR. These
approaches were recently initiated in three other families linked
to chromosome 10q24. In two of these, slot blot analysis using
probes b-TRCP and DACTYLIN exon 6 demonstrated evidence
of a duplicated fragment. In the third family, PFGE analysis
using DACTYLIN exon 6 detected an extra band in an affected
individual. Although further molecular characterization needs
to be performed on these families, these preliminary data
suggest a similar rearrangement with the other seven SHFM3
families.
This study raises several questions for future studies on
SHFM3: (1) what is the mechanism of this rearrangement; (2)
how common is this rearrangement among SHFM patients; and
most importantly, (3) how does this rearrangement cause the
SHFM3 phenotype? In a more general sense, this study
reinforces the importance of Southern and PFGE screening to
detect genomic rearrangements that can be missed by PCR-
based approaches. These techniques will be essential for the
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identification of the rapidly growing family of genomic
disorders.
MATERIALS AND METHODS
SHFM patients
All patients were ascertained for study based upon the presence
of SHFM in one or more limbs. Informed consent was obtained
prior to participation, and these studies were approved by the
Institutional Review Committee of Self Regional Healthcare
(Greenwood, SC, USA). Clinical details, pedigrees and linkage
analysis of families of six of the seven patients (DF, AC, TU,
LS, DH and VB) were previously described (18,24,62,67) and
are summarized in Table 1. In all families, the phenotype was
consistent with non-syndromic SHFM type I (6). Patient TU
and some of his family members have thumb defects
(duplicated and/or triphalangeal) with or without split feet.
Patient RH has SHFM associated with medulloblastoma.
Analysis of SSCP
The sequence data from the full-length DACTYLIN cDNA
(GenBank accession no. AF0281859) and genomic sequences
from BAC clones RP11-190J1, RP11-148E14 and RP11-
573E23 (GenBank accession nos AC010789, AL627144 and
AL627424) were compared using the program Seqman 5.00#
(DNASTAR Inc.) and Blast 2 sequence software
(www.ncbi.nlm.nih.gov/Blast/). Divergence between the two
sequences was taken to be indicative of the presence of an
intron. BLAST analysis also identified a DACTYLIN pseudo-
gene on chromosome 22q11. From the genomic structure,
primers were designed to amplify the coding region of
DACTYLIN for SSCP and sequence analysis. Primer sequences
of the nine exons of the human DACTYLIN gene were designed
using the program Primerselect 5.00# (DNASTAR Inc.).
Individual exons, along with flanking intronic sequences, were
amplified using 50 ng of genomic DNA in a total volume of
10 ml, containing 50 mM of each dNTPs, 1 mCi a32dCTP, 1 mM
of each primer and 0.5 units of Taq DNA polymerase (Sigma,
St Louis, MO, USA). The PCR conditions were as follows: one
cycle at 95C for 4 min; 20 cycles at 95C for 30 s, annealing at
65–55C (decrement of 0.5C/cycle) for 30 s and elongation at
72C for 30 s, then 15 cycles at 95C for 30 s, 55C for 30 s,
72C for 30 s; one cycle at 72C for 5 min. Five microliters of
the radiolabeled PCR product were denatured with 5 ml of stop
solution (95% formamide, 10 mM NaOH, 0.25% bromophenol
blue, 0.25% xylene cyanol) at 94C for 2 min before cooling
on ice. Three microliters of the reaction mixture were loaded
on a 0.5MDETM Acrylamide gel (FMC, Rockland, ME,
USA) prepared following the manufacturer’s procedure.
Electrophoresis was performed at a constant power of 8 W
for 19 h at room temperature. The gel was attached onto 3MM
Whatman filter paper, and dried before exposure to X-ray
Biomax film, (Kodak, Rochester, NY, USA) using standard
techniques.
Sequencing
PCR products were either directly purified or gel-purified using
the QIAquick PCR purification and gel extraction kit
(QIAGEN, Valencia, CA, USA), and sequenced using the
Thermosequenase CyTM5.5 Dye Terminator kit (Amersham
Pharmacia Biotech, Piscataway, NJ, USA) and the forward or
reverse exon-specific primer. A final purification was per-
formed on Autoseq columns (Amersham Pharmacia Biotech,
Piscataway, NJ, USA). All the samples were run on the
automated laser fluorescence (ALF) DNA sequencer
(Pharmacia Biotech, Piscataway, NJ, USA).
Southern analysis
Five micrograms of each patient’s genomic DNA were singly
digested overnight at 37C using EcoRI, PstI, DraI, HindIII,
XbaI, BclI, BglI, BglII, HpaI, BamHI and PvuII enzymes
(New England Biolabs1 Inc., Beverly, MA, USA). After
digestion, samples were electrophoresed on a 0.8% Seakem1
LE agarose gel (BMA, Rockland, ME, USA) and transferred to
a Nytran membrane (Schleicher and Schuell, Keene, NH, USA)
using an alkaline downward transfer procedure (68). The
filters were pre-hybridized for 2–3 h at 65C in hybridization
solution (4 SSPE, 2Denhardt’s solution, 0.5% SDS, 6%
polyethyleneglycol, 40 mg/ml denatured sonicated salmon
Table 1. Clinical features of the seven SHFM patients
Patient Limbsa Phenotype of the affected family members Reference
Hands Feet
DF C, S N/Ab Cleft hands/feet, oligodactyly, syndactyly 32
AC S C, S, O Cleft hands/feet, oligodactyly, syndactyly 32
LS O, S C, S, O Cleft hands/feet, oligodactyly, syndactyly 33
VB N C, S Cleft hands/feet, oligodactyly, syndactyly,
shortening of toes, duplication of digit 2
34
DH N/Ab N/Ab Cleft hands/feet, oligodactyly, syndactyly 33
TU D, T C, S, O Triphalangeal thumb, duplication of the thumb,
nail hypoplasia
35
RHc C, S, O C, S, O Affected mother has cleft hands and feet This paper
aC¼ cleft; S¼ syndactyly; O¼ oligodactyly; N¼ normal; D¼ duplication of a digit; T¼ triphalangeal thumb.
bN/A¼ not available.
cThis patient also had medulloblastoma.
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sperm DNA) before adding the denatured probe. After 12–18 h
of hybridization, filters were washed at 65C, using a final wash
of 0.1SSC, 0.1% SDS. The filters were exposed to X-ray
Biomax film (Kodak, Rochester, NY, USA), using standard
techniques.
Subgenomic library construction
One-hundred and fifty micrograms of patient DNA was
digested and electrophoresed using the same conditions as
for the Southern analysis. The region containing the band of
interest was cut out from the gel and the DNA was electroeluted
and purified using Centricon1 columns (Millipore
Corporation, Bedford, MA, USA). The amount of DNA was
quantified by UV (260 nm) detection and 0.2 mg were used in
the ligation reaction containing 1 mg of the lambda zap
express1 vector (Stratagene, La Jolla, CA, USA). After
packaging, the library was amplified and 5 105 to 1 106
plaques were plated, blotted and probed following the
manufacturer’s protocol (Stratagene, La Jolla, CA, USA).
Lymphoblastoid, human-mouse hybrid cell lines and
DNA extraction
Epstein–Barr virus-transformed lymphoblastoid cell lines were
established from controls and patients following a standard
procedure (69). Human-mouse hybrid cell lines from patients
DF and TU were generated using Conversion technology
(GMP genetics Inc., Waltham, MA, USA). Genomic DNA was
isolated from peripheral blood or from the cell lines by high
salt precipitation (70). Purified DNA was diluted to a
concentration of 105 ng/ml.
PFGE analysis
High molecular weight DNA was isolated in agarose plugs as
previously described (71) using lymphoblastoid cell lines. The
plugs were rinsed twice in 50 ml of TE buffer and then
equilibrated for 30 min in 300 ml of the appropriate endonu-
clease restriction buffer. Excess buffer was removed and the
plugs were incubated at the appropriate temperature for 16 h
with 50 U of endonuclease enzyme per reaction (71). Single
digestion of the DNA plugs was performed using NotI, MluI,
and NruI enzymes. Digested fragments in the range 50–500 kb
were separated by electrophoresis on a 1% Seakem1 Gold
agarose gel (BMA, Rockland, ME, USA) at 200 V for 20 h, at
9C in 0.5TBE running buffer, using a 25 s pulse time on a
Gene Navigator1 apparatus (Amersham Pharmacia Biotech,
Piscataway, NJ, USA). The separation of fragments 400–900 kb
was accomplished by electrophoresis at 170 V for 24 h, at 9C
in 0.5TBE buffer, using a 100 s pulse time.
DNA hybridization probes
DACTYLIN cDNA probes, containing exons 1–4 (DAC 1–4),
exons 2–4 (DAC 2–4) and exons 4–8 (DAC 4–8) were
generated by RT–PCR amplification of RNA extracted from
a lymphoblastoid cell line from a control individual.
Hybridization of individual exons was performed using PCR
products generated with SSCP primers. The genomic sequence
corresponding to the DACTYLIN gene region (contig
NT_033229.1) was submitted to the repeatmasker soft-
ware available at http://ftp.genome.washington.edu/cgi-bin/
RepeatMasker. Intronic probes were then developed using
primers residing in non-repetitive sequences of the
NT_033229.1 contig. Each intronic probe was amplified using
10 ng of BAC DNA when available or 100 ng of total genomic
DNA extracted from a control individual. For intronic probes
larger than 3 kb, long-range PCR was performed using Taq
polymerase with buffer 1 from the Expand Long Template PCR
system (Roche, Indianapolis, IN, USA) following the manu-
facturer’s procedures. Prior to hybridization, intronic probes
were preassociated with sonicated human placental DNA
(Sigma, St Louis, MO, USA) in 50 000-fold excess, at 65C
for 90 min. All the PCR products used as probes were
gel-purified with the QIAquick gel extraction kit (QIAGEN,
Valencia, CA, USA) and sequenced. PCR products were
labeled using the RadprimeTM labeling system (Gibco-
Invitrogen, Carlsbad, CA, USA) in the presence of 50 mCi of
a32dCTP (NEN, Boston, MA, USA).
Quantification of chromosome 10 sequences by
slot-blot analysis
The slot-blot technique was used, with modifications, for the
quantification of chromosome 10 sequences (32,33). In
summary, DNA was quantified by a fluorescence-based assay
using the dye PicoGreen1 (Molecular Probes, Eugene, OR,
USA). The DNA concentration was then adjusted to 50 ng/ml
by dilution in 10 mM Tris–HCl buffer, pH 7.5, 1 mM EDTA and
in 0.2 M of NaOH. The samples were incubated at 37C for
20 min and 12 serial dilutions (0.2–1.5 mg) in 0.15 M NaOH and
0.1SSC were blotted onto GeneScreen Plus1 (NEN1, Life
Science Products, Boston, MA, USA) using a slot blot
apparatus (Minifold II; Schleicher & Schuell, Keene, NH,
USA). After the DNA solution went through, each slot was
washed with 2SSC and the whole membrane was then rinsed
in 2 SSC for 5 min and baked at 80C for 20 min. Blots were
probed with a reference probe, D4S12, prior to the hybridiza-
tion with the test probes from chromosomes 21 and 10. All the
probes were sequenced and tested by Southern hybridization to
confirm their specificity and lack of hybridization to repetitive
sequences. Band intensities were quantified using the Phospho-
imager FUJIX BAS 1000 (Fuji Medical Systems, Stamford,
CT, USA). The chromosome 10 signal ( y axis) was then plotted
against the reference probe signal (x axis) and the slopes were
statistically analyzed and their comparison was assessed by
t-test for significance as previously described (32,33).
To test the efficacy of the slot-blot method, DNAs from a
control individual, patient DF and a trisomic 21 individual were
used. Successive probing with a reference probe, D4S12 and a
chromosome 21 probe, corresponding to the APP gene,
revealed an extra copy of the APP gene only in the trisomic
21 patient. This was characterized by a statistically significant
(P< 0.001) increase of the slope representative of the
correlation between signals from the reference probe and the
chromosome 21 probe (Fig. 6A).
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